Results 151 to 160 of about 8,086 (190)

A TMPRSS2-ERG gene signature predicts prognosis of patients with prostate adenocarcinoma. [PDF]

Clin Transl Med, 2020
Zhou E, Zhang B, Zhu K, Schaafsma E, Kumar RD, Cheng C.   +5 more
europepmc   +1 more source

Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions. [PDF]

Prostate Cancer Prostatic Dis, 2021
Chalmers ZR, Burns MC, Ebot EM, Frampton GM, Ross JS, Hussain MHA, Abdulkadir SA.   +6 more
europepmc   +1 more source

miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. [PDF]

Cancers (Basel), 2021
Bauer S, Ratz L, Heckmann-Nötzel D, Kaczorowski A, Hohenfellner M, Kristiansen G, Duensing S, Altevogt P, Klauck SM, Sültmann H.   +9 more
europepmc   +1 more source

Prostat adenokarsinomunda PCR ile TMPRSS2-ERG gen füzyonunun gösterilmesi

, 2020
133
openaire   +1 more source

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion. [PDF]

J Clin Invest
Ma F, Chen S, Cecchi L, Ersoy-Fazlioglu B, Russo JW, Arai S, Awad S, Calagua C, Xie F, Poluben L, Voznesensky O, Ku AT, Karzai F, Cai C, Einstein DJ, Ye H, Yuan X, Toker A, Taplin ME, Sowalsky AG, Balk SP.   +20 more
europepmc   +1 more source

Exploring therapeutic applications of <i>PTEN, TMPRSS2:ERG</i> fusion, and tumour molecular subtypes in prostate cancer management. [PDF]

Front Oncol
Bugoye FC, Torrorey-Sawe R, Biegon R, Dharsee N, Mafumiko F, Kibona H, Aboud S, Patel K, Mining S.   +8 more
europepmc   +1 more source

Performance of PCA3 and TMPRSS2:ERG Within the Prostate Cancer Prevention Trial Risk Calculator Version 2 in a Lithuanian Cohort. [PDF]

Res Rep Urol
Kemesiene J, Nicolau C, Cholstauskas G, Zviniene K, Lopeta M, Veneviciute S, Asmenaviciute I, Tamosauskaite K, Pikuniene I, Jievaltas M.   +9 more
europepmc   +1 more source

Role of Cell-Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2-ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance. [PDF]

Prostate
Oderda M, Orlando G, Calleris G, Capella G, Delsedime L, Duregon E, di Celle PF, Pacchioni D, Bonapace IM, Zaibunnisa Z, D'Agate D, Montefusco G, Filippini C, Papotti M, Gontero P.   +14 more
europepmc   +1 more source

Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature. [PDF]

World J Surg Oncol
Li Y, Su H, Liu K, Zhao Z, Wang Y, Chen B, Xia J, Yuan H, Huang DS, Gu Y.   +9 more
europepmc   +1 more source

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer. [PDF]

Oncotarget, 2020
Kohaar I, Li Q, Chen Y, Ravindranath L, Young D, Ali A, Sesterhenn IA, Rosner IL, Cullen J, Srivastava S, Freedman M, Petrovics G.   +11 more
europepmc   +1 more source